Identifying the Reactive Metabolites of Tyrosine Kinase Inhibitor Pexidartinib In Vitro Using LC–MS-Based Metabolomic Approaches

[Image: see text] Pexidartinib (PEX, TURALIO), a selective and potent inhibitor of the macrophage colony-stimulating factor-1 receptor, has been approved for the treatment of tenosynovial giant cell tumor. However, frequent and severe adverse effects have been reported in the clinic, resulting in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Xuan, Wang, Yong, MacKenzie, Kevin R., Hakenjos, John M., Chen, Si, Khalil, Saleh M., Jung, Sung Yun, Young, Damian W., Guo, Lei, Li, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445284/
https://www.ncbi.nlm.nih.gov/pubmed/37531179
http://dx.doi.org/10.1021/acs.chemrestox.3c00164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445284/
https://www.ncbi.nlm.nih.gov/pubmed/37531179
http://dx.doi.org/10.1021/acs.chemrestox.3c00164

Ejemplares similares